Effective cardiotonic part of erigeron breviscapus and preparation method thereof

An effective part and technology of breviscapus, applied to the effective part of breviscapine for cardiotonic effect and its preparation method and pharmaceutical preparations containing them, the application of chronic congestive heart failure drugs, the treatment of acute field, can solve the non-compliance and side effects Small and cardiac glycoside components Breviscapita can not be enriched and other issues

Inactive Publication Date: 2011-05-11
TIANJIN PACIFIC PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Breviscapus breviscapus contains cardiac glycosides, which is not only an active ingredient for treating acute and chronic heart failure, but also a toxic ingredient, so its content should be controlled; and the cardiac glycosides in breviscapine can not be enriched. It meets the requirements of modern Chinese medicine "three effects" (high efficiency, quick effect, long-acting), "three small" (small dose, low toxicity, small side effects) and "three stools" (easy to store, carry and take)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Effective cardiotonic part of erigeron breviscapus and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Breviscapus extract 60g, suspended in water, filtered with D 101 Macroporous resin adsorption, first washed with water, then eluted with 10% ethanol, then eluted with 60% ethanol, collected 60% eluent, concentrated to dryness under reduced pressure, and recovered the solvent; the resulting solid was subjected to silica gel column chromatography, Ethyl acetate:methanol=20:1 isocratic elution, each 100mL as a portion, using thin-layer chromatography (developing solvent: chloroform:methanol:water=65:35:10 lower layer, silica gel G thin-layer plate, 3 , 5'-dinitrobenzoic acid reagent for color development) to check the fractions collected, the fractions containing scutellaria breviscapus were combined, concentrated under reduced pressure and then carried out a silica gel column chromatography under the same conditions, after thin layer inspection (thin Layer conditions are the same as above), the fractions with higher content of scutellaria breviscapus were combined, concen...

Embodiment 2

[0029]25g scutellaria extract, mix with 25g silica gel, carry out Soxhlet extraction with ethyl acetate, extract for 12 hours; the extract is concentrated to dryness under reduced pressure, recover the solvent, mix the obtained solid with 5g silica gel, and load the sample on silica gel column, first eluted with ethyl acetate, then eluted with ethyl acetate: ethanol = 25: 1, and tested by TLC (the TLC conditions are the same as in Example 1), the fractions with higher scutellaria content were combined and freeze-dried , to obtain 48 mg of the effective fraction of scutellaria breviscapus, and the content of scutellaria breviscapus was 58% as determined by HPLC; fractions with lower scutellaria scutellaria content could be re-combined for column chromatography.

Embodiment 3

[0031] Scutellaria breviscapus extract 5g carries out reverse-phase column chromatography, filler is carbon-octave bonded phase silica gel, uses 10%~99.5% methanol gradient elution, collects scutellaria breviscapus content through thin-layer inspection (thin-layer condition embodiment 1) The high fractions were combined, concentrated and then spray-dried to obtain 10 mg of the effective fraction of scutellaria breviscapus, which was determined by HPLC to have a content of 56%; the fractions with lower scutellaria content can be re-performed reversed-phase column layer analysis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for preparing an effective cardiotonic part of erigeron breviscapus. The method is characterized in that: erigeron breviscapus extract is used as a raw material, and the extract is separated and purified by adopting one or two of Soxhlet extraction, resin adsorption and column chromatography; water or one or two of 10 to 99.5 percent of organic solvents of alcohol, ester, ketone or alkane and halogenated hydrocarbon is used as solvent or eluant for gradient or isocratic elution; and fractions containing the erigeron breviscapus are combined, concentrated and dried to obtain the effective cardiotonic part containing over 50 percent erigeron breviscapus. Pharmacological experiments prove that the medicinal composition has obvious treatment effect on acute and chronic congestive heart failure.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicines, and more specifically relates to effective fractions of Erigeron breviscapus for cardiotonic action, a preparation method thereof, a pharmaceutical preparation containing them, and the application of the preparation in medicines for treating acute and chronic congestive heart failure. Background technique [0002] Congestive heart failure (congestive heart failure) is due to the impairment of cardiac function. Although the compensatory capacity is exerted, the cardiac output still cannot meet the metabolic needs of the whole body tissue under resting or active conditions, so blood stasis occurs in relevant parts of the body, resulting in a A series of clinical symptoms and signs is a common clinical syndrome. According to the onset of congestive heart failure, it can be divided into acute congestive heart failure and chronic congestive heart failure; according to the sequenc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/27A61P9/04A61K125/00
Inventor 宋德成
Owner TIANJIN PACIFIC PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap